Voya Investment Management LLC Sells 25,547 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Voya Investment Management LLC lessened its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 36.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,254 shares of the company's stock after selling 25,547 shares during the period. Voya Investment Management LLC owned about 0.08% of Janux Therapeutics worth $2,369,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of JANX. FMR LLC lifted its position in Janux Therapeutics by 10.8% during the fourth quarter. FMR LLC now owns 8,669,941 shares of the company's stock worth $464,189,000 after acquiring an additional 845,266 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its position in Janux Therapeutics by 47.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock valued at $163,926,000 after acquiring an additional 986,750 shares during the last quarter. Vanguard Group Inc. boosted its position in Janux Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company's stock valued at $114,379,000 after buying an additional 288,402 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Janux Therapeutics by 596.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company's stock worth $59,429,000 after acquiring an additional 950,557 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Janux Therapeutics by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 714,956 shares of the company's stock valued at $38,288,000 after buying an additional 52,362 shares during the period. Institutional investors and hedge funds own 75.39% of the company's stock.

Wall Street Analysts Forecast Growth

JANX has been the subject of several recent analyst reports. Wedbush reiterated an "outperform" rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Finally, Scotiabank dropped their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $95.25.

Janux Therapeutics Stock Up 0.6 %

NASDAQ:JANX traded up $0.16 during mid-day trading on Wednesday, hitting $25.70. 1,558,339 shares of the stock traded hands, compared to its average volume of 859,842. The business's 50-day moving average price is $29.61 and its 200 day moving average price is $42.21. The company has a market cap of $1.52 billion, a PE ratio of -21.97 and a beta of 3.24. Janux Therapeutics, Inc. has a 12-month low of $22.47 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Janux Therapeutics news, Director Ra Capital Management, L.P. bought 110,206 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were bought at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the purchase, the director now directly owns 10,141,287 shares of the company's stock, valued at $314,582,722.74. This trade represents a 1.10 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $30.00, for a total value of $100,020.00. Following the transaction, the insider now directly owns 82,139 shares in the company, valued at $2,464,170. This trade represents a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,001 shares of company stock worth $313,964 in the last ninety days. 29.40% of the stock is currently owned by insiders.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.